KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Operations (2016 - 2026)

Bio-Rad Laboratories has reported Cash from Operations over the past 18 years, most recently at 108100000.0 for Q1 2026.

  • Quarterly Cash from Operations fell 16.78% to 108100000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 510400000.0 through Mar 2026, down 0.95% year-over-year, with the annual reading at 532200000.0 for FY2025, 16.92% up from the prior year.
  • Cash from Operations was 108100000.0 for Q1 2026 at Bio-Rad Laboratories, down from 164900000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 164900000.0 in Q4 2025 and troughed at 10990000.0 in Q3 2022.
  • The 5-year median for Cash from Operations is 98066000.0 (2023), against an average of 97929411.76.
  • Year-over-year, Cash from Operations plummeted 95.23% in 2022 and then surged 789.09% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 79610000.0 in 2022, then rose by 1.75% to 81004000.0 in 2023, then skyrocketed by 53.33% to 124200000.0 in 2024, then surged by 32.77% to 164900000.0 in 2025, then crashed by 34.45% to 108100000.0 in 2026.
  • Per Business Quant, the three most recent readings for BIO's Cash from Operations are 108100000.0 (Q1 2026), 164900000.0 (Q4 2025), and 120900000.0 (Q3 2025).